Virtual bioequivalence-guided PBBM prediction for ibuprofen/diphenhydramine citrate tablets: impact of dissolution variability and clinical standard development.

Authors

Zilong Wang, Zhihai Cao, Chun Guo, Qian Zhang, Renpeng Zhou, Jian Chen, Feng Su, Wei Liu, Zhaoxing Chu, Liang Zheng, Wei Hu

Published in

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. Volume 34. Issue 5. Sep 07, 2026. Epub Sep 07, 2026.

Abstract

This study aimed to integrate in vitro dissolution testing, in vivo pharmacokinetic (PK) studies, and computational simulation to develop a physiologically based biopharmaceutics model (PBBM) for fixed-dose combination ibuprofen/diphenhydramine citrate tablets, thereby evaluating bioequivalence (BE) and establishing a dissolution safe space. Initially, a PBBM model was constructed using B²O Simulator software. Subsequently, an integrated approach was employed, combining dissolution profiles with physiological parameters to develop a virtual bioequivalence (VBE) model. Through simulations involving virtual batches exhibiting diverse dissolution characteristics, the safe dissolution range was determined. Consequently, the PBBM models for ibuprofen and diphenhydramine were successfully validated. Furthermore, the VBE model demonstrated favorable bioequivalence, with an absolute average fold error (AAFE) of less than 1.5 between predicted and observed values for key PK parameters (C_max and AUC). Scenario analyses supported a formulation- and medium-specific dissolution criterion of no less than 85% dissolution within 30 min for both APIs in pH 6.5 phosphate buffer. Additionally, scenario analyses suggested that, within the simulated two-treatment, two-period crossover settings evaluated in this study, a sample size of approximately 40 subjects may represent a practical lower bound for obtaining stable BE conclusions. In conclusion, this study provides a product-specific, model-informed workflow for bioequivalence risk assessment of ibuprofen/diphenhydramine citrate tablets. The application of PBBM and VBE modeling offers guidance for quantitative BE risk assessment, thereby holding promise to accelerate the development process while reducing associated costs. (The bioequivalence study in healthy subjects was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University [ChiCTR registration number: ChiCTR2500106504; approved: March 12, 2023].).

PMID:
42704568
Bibliographic data and abstract were imported from PubMed on 08 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.